News

mRNA Based COVID-19 Vaccines Are Less Likely To Induce Allergic Conditions

mRNA Based COVID-19 Vaccines Are Less Likely To Induce Allergic Conditions

New research found that the risk of severe allergic reactions is very low with COVID-19 vaccines which are based on mRNA.

mRNA Based COVID-19 Vaccines Are Less Likely To Induce Allergic Conditions

The Findings of the study were published on Tuesday in the Journal of American Medical Association. It suggested that the conditions of allergic reactions are rare after receiving the vaccine doses and even if it occurs it is quickly resolvable. 

mRNA Based COVID-19 Vaccines Are Less Likely To Induce Allergic Conditions

The head of the researchers’ team was Dr. Kimberly Blumenthal, the co-director of the Clinical Epidemiology Program at Massachusetts General Hospital’s Division of Rheumatology, Allergy, and Immunology. 

Dr. Blumenthal said that both the vaccines that have received emergency authorization initially against the COVID-19 pandemic are the first of their kind and they are remarkably effective and safe among all populations. In such a situation with the pandemic in the present as well as the future, it is important to have accurate data on allergic reactions to these vaccines. 

All allergic reactions were documented during the study by Blumenthal and her team. Their main concern was anaphylaxis. The sturdy includes employees at the health system that includes Mass General and Brigham and Women’s Hospital, both in Boston. 52,800 employees were surveyed after they received their first doses of the vaccine. Out of them, 2% had an allergic reaction. Per 10,000 individuals, the condition of anaphylaxis was detected at a rate of 2.47. 

Through the hospital’s news release, Blumenthal said that it is largely comparable to anaphylactic reactions from common antibiotics when putting this in perspective. 

The U.S Centers for Disease Control and Prevention had already conducted a similar survey lately. According to their conclusions, the rate of anaphylaxis was between 0.025 – 0.11 per 10,000 individuals. Since the current study proves there is a little bit more risk, experts said that it is still compatible because the new study has come up with a very low figure in the risk. The study also needed to reassure those who were enrolled in the study, to check whether they had a prior history of any allergic condition to food or drugs. 

Another researcher who was a part of the study, Dr. Paige Wickner, medical director of the Department of Quality and Safety at Brigham and Women’s, said that a prior episode of anaphylaxis was the only allergy exclusion for the vaccine. This is due to an inactive ingredient in the vaccine that is called polyethylene glycol. Another possibility is the presence of polysorbate, a cross-reactive component.

In the press release, Wickner also said that all of the cases reported during their study with the condition of anaphylaxis have recovered and it is another important aspect of their study. She added that nobody had the difficulty of anaphylactic shock or required a breathing tube, even for just a while. 

Both the vaccines developed by Moderna and Pfizer are works on mRNA against the coronavirus. But the third vaccine approved by the CDC and FDA, which is manufactured by Johnson & Johnson doesn’t come under this category. Further studies on the side effects of the J&J vaccine need to be conducted since it works on employing a cold harmless virus. 

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular

To Top